Genex Pharmaceutical Inc (GENX) Prix

Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin and currently employs 86 full-time employees. The company went IPO on 2006-05-23. The Company’s main business is engaged in producing and distributing Reconstituted Bone Xenograft (RBX). The RBX is a medical device that accelerates bone healing. The firm distributes its medical devices to hospitals as well as other medical device customers that are not hospitals.